5 April 2011
Pharma major Cipla has applied for a “voluntary license” for Merck’s anti-HIV drug Isentress saying the drug is exorbitantly priced and is inaccessible to needy patients in India.
What this means is that Cipla is asking Merck to share the technical know-how for making the drug, so that Cipla can make and sell a generic version in India, and in turn pay a royalty to Merck.
From MoneyControl.com, “Cipla Tells Merck your anti-AIDS drug too costly in India" (4 April 2011)
Regularly updated news feed of updates to the online version of Untangling the Web as well as related news articles.